{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:24:50Z","timestamp":1787199890163,"version":"build-2736575974"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ijgc.2026.104896","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:09:10Z","timestamp":1785510550000},"page":"104896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From regulatory approval to equity: the Brazilian poly(adenosine diphosphate-ribose) polymerase inhibitor experience"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5966-8940","authenticated-orcid":false,"given":"Let\u00edcia Vecchi","family":"Leis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7713-0100","authenticated-orcid":false,"given":"Mariana","family":"Scaranti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijgc.2026.104896_bib1","unstructured":"Instituto Nacional de C\u00e2ncer (BR). Estimativa 2026: incid\u00eancia de c\u00e2ncer no Brasil [Internet]. Rio de Janeiro: INCA; 2026 [cited 2026 Jul 16]. Available from: https:\/\/ninho.inca.gov.br\/jspui\/handle\/123456789\/17914"},{"key":"10.1016\/j.ijgc.2026.104896_bib2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JGO.19.00170","article-title":"Recommendations for advancing the diagnosis and management of hereditary breast and ovarian cancer in Brazil","volume":"6","author":"Achatz","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"15","key":"10.1016\/j.ijgc.2026.104896_bib3","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104896_bib4","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2026.104896_bib5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ijgc.2026.104896_bib6","unstructured":"Instituto Brasileiro de Geografia e Estat\u00edstica. Pesquisa Nacional de Sa\u00fade 2019: aten\u00e7\u00e3o prim\u00e1ria \u00e0 sa\u00fade e informa\u00e7\u00f5es antropom\u00e9tricas [Internet]. Rio de Janeiro: IBGE; 2020 [cited 2026 Jul 16]. Available from: https:\/\/biblioteca.ibge.gov.br\/index.php\/biblioteca-catalogo?id=2101758&view=detalhes"},{"key":"10.1016\/j.ijgc.2026.104896_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ygyno.2024.02.021","article-title":"Real world challenges and disparities in the systemic treatment of ovarian cancer","volume":"185","author":"Nogueira-Rodrigues","year":"2024","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104896_bib8","unstructured":"Brasil. Minist\u00e9rio da Sa\u00fade. Governo do Brasil garante oferta de 23 novos medicamentos de alta tecnologia para o tratamento do c\u00e2ncer no SUS [Internet]. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2026 May 15 [cited 2026 July 16]. Available from: https:\/\/www.gov.br\/inca\/pt-br\/assuntos\/noticias\/2026\/sus-oferece-23-novos-medicamentos-para-o-tratamento-do-cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26004275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T03:58:08Z","timestamp":1787198288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26004275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":8,"alternative-id":["S1048891X26004275"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104896","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From regulatory approval to equity: the Brazilian poly(adenosine diphosphate-ribose) polymerase inhibitor experience","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104896","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104896"}}